A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use

G. Astori, W. Malangone, V. Adami, A. Risso, L. Dorotea, E. Falasca, L. Marini, R. Spizzo, L. Bigi, P. Sala, E. Tonutti, F. Biffoni, C. Rinaldi, G. Del Frate, M. Pittino, A. Degrassi

Research output: Contribution to journalArticle

Abstract

To obtain long-term engraftment and hematopoiesis in myeloablated patients, the cell population used for hematopoietic reconstitution should include a sufficient number of early pluripotent hematopoietic stem cells (HSCs), along with committed cells from the various lineages. For this purpose, the small subset of CD34+ cells purified from different sources must be expanded ex vivo. Since cytokines may induce both proliferation and differentiation, expansion would provide a cell population comprising committed as well as uncommitted cells. Optimization of HSC expansion methods could be obtained by a combination of cytokines able to sustain renewal of pluripotent cells yet endowed with poor differentiation potential. We used variations of the combinations of cytokines described by Brugger et al. [W. Brugger, S. Heimfels, R. J. Berenson, R. Mertelsmann, and L. Kanz (1995) N. Engl. J. Med. 333, 283-287] and Piacibello et al. [W. Piacibello, F. Sanavio, L. Garetto, A. Severino, D. Bergandi, J. Ferrario, F. Fagioli, M. Berger, and M. Aglietta (1997) Blood 89, 2644-2653] to expand UCB CD34+ cells and monitored proliferation rate and phenotype after 14 days of culture. Several hematopoietic lineage-associated surface antigens were evaluated. Our data show that flt3L and thrombopoietin in combination with IL-3, while sustaining a high CD34+ proliferation rate, provide a relatively low enrichment in very early uncommitted CD34+/CD38- cells. Conversely, in the absence of IL-3, they are less effective in inducing proliferation yet significantly increase the number of CD34+/CD38- cells. A combination of the above protocols, applied simultaneously to aliquots of the same sample, would allow expansion of both committed and pluripotent HSC. This strategy may represent a significant improvement for clinical applications.

Original languageEnglish
Pages (from-to)715-724
Number of pages10
JournalBlood cells, molecules & diseases
Volume27
Issue number4
DOIs
Publication statusPublished - 2001

Keywords

  • CD34+ cells
  • Ex vivo expansion
  • Hematopoietic stem cells
  • Umbilical cord blood

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Fingerprint Dive into the research topics of 'A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use'. Together they form a unique fingerprint.

  • Cite this

    Astori, G., Malangone, W., Adami, V., Risso, A., Dorotea, L., Falasca, E., Marini, L., Spizzo, R., Bigi, L., Sala, P., Tonutti, E., Biffoni, F., Rinaldi, C., Del Frate, G., Pittino, M., & Degrassi, A. (2001). A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use. Blood cells, molecules & diseases, 27(4), 715-724. https://doi.org/10.1006/bcmd.2001.0439